Gilead Sciences Statistics

Total Valuation

Gilead Sciences has a market cap or net worth of EUR 156.49 billion. The enterprise value is 167.38 billion.

Market Cap	156.49B
Enterprise Value	167.38B

Important Dates

The last earnings date was Tuesday, February 10, 2026.

Earnings Date	Feb 10, 2026
Ex-Dividend Date	Dec 15, 2025

Share Statistics

Current Share Class	1.24B
Shares Outstanding	n/a
Shares Change (YoY)	n/a
Shares Change (QoQ)	-0.08%
Owned by Insiders (%)	0.10%
Owned by Institutions (%)	89.29%
Float	1.24B

Valuation Ratios

The trailing PE ratio is 21.59 and the forward PE ratio is 17.08.

PE Ratio	21.59
Forward PE	17.08
PS Ratio	6.24
PB Ratio	8.12
P/TBV Ratio	n/a
P/FCF Ratio	19.43
P/OCF Ratio	18.34
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

The stock's EV/EBITDA ratio is 13.41, with an EV/FCF ratio of 20.78.

EV / Earnings	23.09
EV / Sales	6.72
EV / EBITDA	13.41
EV / EBIT	16.74
EV / FCF	20.78

Financial Position

The company has a current ratio of 1.55, with a Debt / Equity ratio of 1.13.

Current Ratio	1.55
Quick Ratio	1.23
Debt / Equity	1.13
Debt / EBITDA	1.73
Debt / FCF	2.70
Interest Coverage	11.54

Financial Efficiency

Return on equity (ROE) is 40.66% and return on invested capital (ROIC) is 26.86%.

Return on Equity (ROE)	40.66%
Return on Assets (ROA)	12.52%
Return on Invested Capital (ROIC)	26.86%
Return on Capital Employed (ROCE)	25.03%
Weighted Average Cost of Capital (WACC)	6.03%
Revenue Per Employee	1.48M
Profits Per Employee	426,351
Employee Count	17,000
Asset Turnover	0.50
Inventory Turnover	3.58

Taxes

In the past 12 months, Gilead Sciences has paid 1.10 billion in taxes.

Income Tax	1.10B
Effective Tax Rate	13.13%

Stock Price Statistics

The stock price has increased by +18.96% in the last 52 weeks. The beta is 0.39, so Gilead Sciences's price volatility has been lower than the market average.

Beta (5Y)	0.39
52-Week Price Change	+18.96%
50-Day Moving Average	115.32
200-Day Moving Average	103.32
Relative Strength Index (RSI)	55.41
Average Volume (20 Days)	2,178

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	2.95

Income Statement

In the last 12 months, Gilead Sciences had revenue of EUR 25.08 billion and earned 7.25 billion in profits. Earnings per share was 5.77.

Revenue	25.08B
Gross Profit	19.77B
Operating Income	10.06B
Pretax Income	8.34B
Net Income	7.25B
EBITDA	12.42B
EBIT	10.06B
Earnings Per Share (EPS)	5.77

Full Income Statement

Balance Sheet

The company has 8.19 billion in cash and 21.75 billion in debt, giving a net cash position of -11.03 billion.

Cash & Cash Equivalents	8.19B
Total Debt	21.75B
Net Cash	-11.03B
Net Cash Per Share	n/a
Equity (Book Value)	19.26B
Book Value Per Share	15.58
Working Capital	5.56B

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was 8.53 billion and capital expenditures -479.51 million, giving a free cash flow of 8.05 billion.

Operating Cash Flow	8.53B
Capital Expenditures	-479.51M
Free Cash Flow	8.05B
FCF Per Share	n/a

Full Cash Flow Statement

Margins

Gross margin is 78.84%, with operating and profit margins of 40.14% and 28.90%.

Gross Margin	78.84%
Operating Margin	40.14%
Pretax Margin	33.27%
Profit Margin	28.90%
EBITDA Margin	49.51%
EBIT Margin	40.14%
FCF Margin	32.12%

Dividends & Yields

This stock pays an annual dividend of 2.76, which amounts to a dividend yield of 2.17%.

Dividend Per Share	2.76
Dividend Yield	2.17%
Dividend Growth (YoY)	-3.29%
Years of Dividend Growth	n/a
Payout Ratio	47.74%
Buyback Yield	0.24%
Shareholder Yield	2.44%
Earnings Yield	4.63%
FCF Yield	5.15%

Dividend Details

Stock Splits

The last stock split was on January 28, 2013. It was a forward split with a ratio of 2.

Last Split Date	Jan 28, 2013
Split Type	Forward
Split Ratio	2

Scores

Gilead Sciences has an Altman Z-Score of 3.9 and a Piotroski F-Score of 7.

Altman Z-Score	3.9
Piotroski F-Score	7